Mereo BioPharma Group (NASDAQ:MREO) Downgraded to Hold at Zacks Investment Research
According to Zacks, “Mereo BioPharma Group PLC is a biopharmaceutical company. It is focused on development and commercialization of therapeutics for patients with rare diseases. The company’s product pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab which are in clinical stage. Mereo BioPharma Group PLC is based in London, United Kingdom. “
MREO has been the topic of several other reports. Leerink Swann started coverage on Mereo BioPharma Group in a research note on Thursday, October 10th. They issued an outperform rating on the stock. Svb Leerink restated an outperform rating on shares of Mereo BioPharma Group in a research note on Thursday, October 10th.
About Mereo BioPharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
Further Reading: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.